BLUE vs. ALEC, PROK, ADAP, FUSN, CRBU, ALLO, AURA, VYGR, FDMT, and AGEN
Should you be buying bluebird bio stock or one of its competitors? The main competitors of bluebird bio include Alector (ALEC), ProKidney (PROK), Adaptimmune Therapeutics (ADAP), Fusion Pharmaceuticals (FUSN), Caribou Biosciences (CRBU), Allogene Therapeutics (ALLO), Aura Biosciences (AURA), Voyager Therapeutics (VYGR), 4D Molecular Therapeutics (FDMT), and Agenus (AGEN). These companies are all part of the "biological products, except diagnostic" industry.
Alector (NASDAQ:ALEC) and bluebird bio (NASDAQ:BLUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, community ranking, institutional ownership, media sentiment, dividends, valuation and profitability.
In the previous week, bluebird bio had 1 more articles in the media than Alector. MarketBeat recorded 3 mentions for bluebird bio and 2 mentions for Alector. bluebird bio's average media sentiment score of 1.43 beat Alector's score of 0.36 indicating that Alector is being referred to more favorably in the media.
Alector presently has a consensus target price of $13.70, suggesting a potential upside of 152.77%. bluebird bio has a consensus target price of $7.62, suggesting a potential upside of 91.00%. Given bluebird bio's stronger consensus rating and higher probable upside, equities analysts plainly believe Alector is more favorable than bluebird bio.
Alector has a net margin of -146.80% compared to Alector's net margin of -419.64%. Alector's return on equity of -34.32% beat bluebird bio's return on equity.
bluebird bio received 891 more outperform votes than Alector when rated by MarketBeat users. Likewise, 72.27% of users gave bluebird bio an outperform vote while only 59.75% of users gave Alector an outperform vote.
69.7% of Alector shares are owned by institutional investors. Comparatively, 87.4% of bluebird bio shares are owned by institutional investors. 14.0% of Alector shares are owned by company insiders. Comparatively, 2.1% of bluebird bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Alector has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, bluebird bio has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.
Alector has higher revenue and earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.
Summary
bluebird bio beats Alector on 10 of the 18 factors compared between the two stocks.
Get bluebird bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
bluebird bio Competitors List
Related Companies and Tools